Benzinga | Aug 10, 2021 08:06AM EDT

Rain Therapeutics Q2 EPS $(0.39) Beats $(0.60) Estimate

Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.60) by 35 percent.